Geode Capital Management LLC Acquires 129,654 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Geode Capital Management LLC grew its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 12.5% during the third quarter, Holdings Channel reports. The institutional investor owned 1,164,204 shares of the company’s stock after purchasing an additional 129,654 shares during the quarter. Geode Capital Management LLC’s holdings in Perspective Therapeutics were worth $15,546,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. nVerses Capital LLC bought a new stake in Perspective Therapeutics in the third quarter valued at approximately $57,000. US Bancorp DE raised its holdings in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in Perspective Therapeutics during the 2nd quarter valued at $117,000. Point72 DIFC Ltd purchased a new stake in Perspective Therapeutics during the 2nd quarter valued at $118,000. Finally, Intech Investment Management LLC bought a new stake in Perspective Therapeutics in the 3rd quarter worth $137,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Wall Street Analyst Weigh In

CATX has been the topic of a number of research analyst reports. Wedbush restated an “outperform” rating and set a $11.00 price target (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Truist Financial started coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective on the stock. Oppenheimer decreased their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Royal Bank of Canada cut their price target on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a report on Monday, November 25th. Finally, UBS Group started coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Perspective Therapeutics has an average rating of “Moderate Buy” and an average target price of $15.14.

Perspective Therapeutics Trading Down 3.0 %

Shares of CATX opened at $3.19 on Monday. Perspective Therapeutics, Inc. has a 1-year low of $2.70 and a 1-year high of $19.05. The firm has a fifty day simple moving average of $6.86 and a two-hundred day simple moving average of $10.76.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The company had revenue of $0.37 million for the quarter. As a group, analysts forecast that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Insider Activity at Perspective Therapeutics

In other news, CEO Johan M. Spoor purchased 14,500 shares of the business’s stock in a transaction on Monday, November 25th. The stock was acquired at an average price of $3.78 per share, for a total transaction of $54,810.00. Following the acquisition, the chief executive officer now directly owns 152,072 shares of the company’s stock, valued at $574,832.16. This represents a 10.54 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Heidi Henson purchased 25,975 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were acquired at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the purchase, the director now owns 25,975 shares of the company’s stock, valued at $100,003.75. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 67,570 shares of company stock worth $256,789. 3.52% of the stock is owned by corporate insiders.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.